Explore the vast range of titles available.

\"Robert Harrison provides new insight into grass-roots Reconstruction after the Civil War and into the lives of those of those most deeply affected, the newly emancipated African Americans\"-- Provided by publisher.

This article reports the changes to virus taxonomy approved and ratified by the International Committee on Taxonomy of Viruses (ICTV) in February 2019. Of note, in addition to seven new virus families, the ICTV has approved, by an absolute majority, the creation of the realm Riboviria, a likely monophyletic group encompassing all viruses with positive-strand, negative-strand and double-strand genomic RNA that use cognate RNA-directed RNA polymerases for replication.

The World Health Organization's strategy to halve snakebite mortality and morbidity by 2030 includes an emphasis on a risk-benefit process assessing the preclinical efficacy of antivenoms manufactured for sub-Saharan Africa. To assist this process, we systematically collected, standardised and analysed all publicly available data on the preclinical efficacy of antivenoms designed for sub-Saharan Africa. Using a systematic search of publication databases, we focused on publicly available preclinical reports of the efficacy of 16 antivenom products available in sub Saharan Africa. Publications since 1999 reporting the industry standard intravenous pre-incubation method of murine in vivo neutralisation of venom lethality (median effective dose [ED50]) were included. Eighteen publications met the criteria. To permit comparison of the several different reported ED50 values, it was necessary to standardise these to microlitre of antivenom resulting in 50% survival of mice challenged per milligram of venom (μl/mg). We were unable to identify publicly available preclinical data on four antivenoms, whilst data for six polyspecific antivenoms were restricted to a small number of venoms. Only four antivenoms were tested against a wide range of venoms. Examination of these studies for the reporting of key metrics required for interpreting antivenom ED50s were highly variable, as evidenced by eight different units being used for the described ED50 values. There is a disturbing lack of (i) preclinical efficacy testing of antivenom for sub Saharan Africa, (ii) publicly available reports and (iii) independent scrutiny of this medically important data. Where reports do exist, the methods and metrics used are highly variable. This prevents comprehensive meta-analysis of antivenom preclinical efficacy, and severely reduces the utility of antivenom ED50 results in the decision making of physicians treating patients and of national and international health agencies. Here, we propose the use of a standardised result reporting checklist to resolve this issue. Implementation of these straightforward steps will deliver uniform evaluation of products across laboratories, facilitate meta-analyses, and contribute vital information for designing the clinical trials needed to achieve the WHO target of halving snakebite morbidity and mortality by 2030.

Annotation Hugh Trevor-Roper's experiences working for the Secret Intelligence Service (MI6) during the war had a profound impact on him and he later observed the world of intelligence with particular sharpness. To him, the subject of wartime espionage was as worthy of profound investigation and reflection as events from the more distant past. Expressing his observations through some of his most ironic and entertaining prose, Trevor-Roper wrote with a freedom he could not express publicly due to the Official Secrets Act. Based on previously unpublished material - including an extraordinary and previously-unseen correspondence with the exiled spy Kim Philby - this is a first-hand account of the intelligence world in World War II and its aftermath.

An essential resource for ceramicists, studios or schools looking for inspiration to reclaim, reuse and recycle in their studio or work. Producing work that is not only beautifully designed and produced, but is also environmentally friendly and socially responsible is now more important than ever. In Sustainable Ceramics, pioneer Robert Harrison draws on more than four decades of making, and a wealth of experience shared by other artists to present you with a range of practical possibilities. This book presents you all the factors to consider when going 'green', from fuels and alternative firing technology to energy-saving methods, sustainable ways to collect and use clay itself, and ways to deal with or recycle your waste materials and save water. He suggests simple and achievable methods by which to reduce the carbon footprint of your ceramic art, and draws on interviews and examples by practitioners who reclaim, reuse and recycle in their studio or work.

This text concludes 'The Industrialisation of Soviet Russia,' an authoritative account of the Soviet Union's industrial transformation between 1929 and 1939. The volume before this one covered the 'good years' (in economic terms) of 1934 to 1936. The present volume has a darker tone: beginning from the Great Terror, it ends with the Hitler-Stalin pact and the outbreak of World War II in Europe. During that time, Soviet society was repeatedly mobilised against internal and external enemies, and the economy provided one of the main arenas for the struggle. This was expressed in waves of repression, intensive rearmament, the increased regimentation of the workforce and the widespread use of forced labour.

Antivenom is the treatment of choice for snakebite, which annually kills an estimated 32,000 people in sub-Saharan Africa and leaves approximately 100,000 survivors with permanent physical disabilities that exert a considerable socioeconomic burden. Over the past two decades, the high costs of the most polyspecifically-effective antivenoms have sequentially reduced demand, commercial manufacturing incentives and production volumes that have combined to create a continent-wide vacuum of effective snakebite therapy. This was quickly filled with new, less expensive antivenoms, many of which are of untested efficacy. Some of these successfully marketed antivenoms for Africa are inappropriately manufactured with venoms from non-African snakes and are dangerously ineffective. The uncertain efficacy of available antivenoms exacerbates the complexity of designing intervention measures to reduce the burden of snakebite in sub-Saharan Africa. The objective of this study was to preclinically determine the ability of antivenoms available in Kenya to neutralise the lethal effects of venoms from the most medically important snakes in East Africa. We collected venom samples from the most medically important snakes in East Africa and determined their toxicity in a mouse model. Using a 'gold standard' comparison protocol, we preclinically tested the comparative venom-neutralising efficacy of four antivenoms available in Kenya with two antivenoms of clinically-proven efficacy. To explain the variant efficacies of these antivenoms we tested the IgG-venom binding characteristics of each antivenom using in vitro IgG titre, avidity and venom-protein specificity assays. We also measured the IgG concentration of each antivenom. None of the six antivenoms are preclinically effective, at the doses tested, against all of the most medically important snakes of the region. The very limited snake polyspecific efficacy of two locally available antivenoms is of concern. In vitro assays of the abilities of 'test' antivenom IgGs to bind venom proteins were not substantially different from that of the 'gold standard' antivenoms. The least effective antivenoms had the lowest IgG content/vial. Manufacture-stated preclinical efficacy statements guide decision making by physicians and antivenom purchasers in sub-Saharan Africa. This is because of the lack of both clinical data on the efficacy of most of the many antivenoms used to treat patients and independent preclinical assessment. Our preclinical efficacy assessment of antivenoms available in Kenya identifies important limitations for two of the most commonly-used antivenoms, and that no antivenom is preclinically effective against all the regionally important snakes. The potential implication to snakebite treatment is of serious concern in Kenya and elsewhere in sub-Saharan Africa, and underscores the dilemma physicians face, the need for clinical data on antivenom efficacy and the medical and societal value of establishing independent preclinical antivenom-efficacy testing facilities throughout the continent.